EDAP reports second quarter 2024 financial results

• Record Q2 2024 total global revenue of EUR 15.8 million (USD 17.0 million) increased 10.6% versus Q2 2023
• Record first half 2024 total global revenue of EUR 30.7 million (USD 33.1 million) increased by 5.6% compared to the first half of 2023
• Strong US Focal One HIFU procedure growth in Q2 2024 of +63% YoY
• Company will host a conference call and webcast today, August 28, at 8:30 a.m. EDT

LYON, France, August 28, 2024 – EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy therapies, today reported unaudited consolidated financial results for the second quarter of 2024.

“We continue to see increased demand for our patented, industry-leading Focal One robotic HIFU technology platform. In the second quarter, we placed five Focal One systems, including placements at two additional National Cancer Institute (NCI)-designated comprehensive cancer centers. A growing number of top cancer research and treatment centers continue to use Focal One to help patients treat their prostate cancer, reflecting the innovation and positive clinical outcomes of our industry-leading robotic HIFU platform,” said Ryan Rhodes, Chief Executive Officer of EDAP TMS. “We also experienced strong year-over-year procedure growth, indicating the growing adoption of robotic HIFU among urologists at both academic and community hospitals.